AbbVie has received approval in the European Union for a new indication for its top-selling drug, Humira (adalimumab), for treating active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS treatment. HS, sometimes referred to as “acne inversa” by dermatologists, is a chronic inflammatory skin disease.

Humira, which posted 2014 sales of $12.5 billion, is now approved for 13 indications on a global basis. It is approved for use in adults with moderate to severe rheumatoid arthritis, severe active ankylosing spondylitis(AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate to severe chronic plaque psoriasis, active and progressive psoriatic arthritis, moderately to severely active Crohn’s Disease, moderately to severely active ulcerative colitis and active moderate to severe hidradenitis suppurativa. It is also approved for use in pediatric patients with active enthesitis-related arthritis, severe chronic plaque psoriasis, severe active Crohn’s disease, and active polyarticular juvenile idiopathic arthritis in patients who have had inadequate response to prior therapy.

Source: AbbVie